Can Pfizer’s $10.5bn Innovent deal rebuild confidence in its oncology pipeline?
Pfizer’s $10.5bn Innovent deal targets ADCs and multispecific antibodies. Find out why China biotech is reshaping oncology pipelines.
Can Eli Lilly’s $3bn Haisco deal deepen big pharma’s China drug discovery pipeline?
Eli Lilly’s Haisco deal could be worth over $3 billion. Find out why China-originated drug discovery is becoming harder to ignore.
Why Pfizer’s $10.5bn Innovent Biologics deal matters for the next wave of cancer medicines
Pfizer’s $10.5bn Innovent alliance deepens its oncology reset. Can early ADC and multispecific bets become global cancer drugs?
Why Bristol Myers Squibb’s $15.2bn Hengrui alliance signals a pipeline reset
Big Pharma needs faster pipelines. Bristol Myers Squibb’s Hengrui pact shows why China’s R&D engine is becoming harder to ignore.
With AlloJoin Phase 3 in motion, Fosun Kairos takes lead on stem cell therapy rollout in China
ElpasBio partners with Fosun Kairos to commercialize AlloJoin stem cell therapy for KOA in China. Find out what this deal means for the cell therapy market.
Innovent’s mazdutide earns Nature spotlight: Are dual GCG/GLP-1 agonists set to reshape diabetes and obesity care?
Innovent Biologics, Inc. has achieved a landmark moment in China’s clinical research trajectory with the back-to-back publication of two Phase 3 clinical trials of mazdutide, a dual GCG/GLP-1 receptor agonist, in Nature as Accelerated Article Previews. These studies, known as DREAMS-1 and DREAMS-2, evaluated the drug as monotherapy and as an add-on therapy in Chinese […]
Can Sanyou Biopharmaceuticals and KanryBio Biotechnology disrupt the global companion diagnostics market?
Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and Wenzhou KanryBio Biotechnology Co., Ltd. have entered into a strategic collaboration focused on co-developing high-value reagents and products for biomarker assay kits. Announced on December 10, 2025, this partnership aims to combine Sanyou Biopharmaceuticals’ global leadership in AI-driven molecular discovery with KanryBio Biotechnology’s capabilities in kit product development and […]